Blue Devil Pharmaceuticals

Blue Devil Pharmaceuticals is a private biotechnology company based in Durham, North Carolina, focused on the discovery and development of novel small molecule therapeutics. The company was founded by Dr. David Gooden, Director of the Duke University Small Molecule Synthesis Facility, to commercialize research originating from the university's chemical biology programs. Its primary research focus involves the development of inhibitors targeting the Myc-Max protein-protein interaction, a well-known but challenging driver of various cancers. By utilizing advanced medicinal chemistry and synthetic techniques, the company aims to create potent and selective agents for oncology indications. Blue Devil Pharmaceuticals operates as an early-stage R&D entity, leveraging its close ties to the Duke University research ecosystem to translate academic chemical innovations into potential clinical candidates.